Strive Pharmacy
Strive Pharmacy scored 55/100 on Panya's 11-signal vendor rubric. Each signal is scored 0 to 100, the methodology is public, and our affiliate posture is flat-fee · never pay-to-rank. Below is the full per-signal breakdown.
- COA on every lot503A patient-specific compounding; per-batch COA depth varies by state and product65
- Cold-chain verifiedlicensed pharmacy supply chain70
- Rx legality50-state licensed. Enforcement discretion for 503A 'essentially a copy' compounding ended Feb 11, 2025 · post-2025 only documented medical-necessity (specific allergy to inactive ingredient, clinically-justified non-standard concentration) is permissible. September 2025 Arizona Board of Pharmacy inspection found continued single-ingredient compounding past the federal exemption window.55
- Compound identity70
- Dose accuracy70
- Endotoxin testing503A requirements lower than 503B outsourcing facilities55
- Refund postureprescription model; refund routed via prescribing clinic55
- Channel clarityRx-only; clinic-mediated; LegitScript-listed. Volume narrows materially under the post-2025 medical-necessity-only path; channel still routable for documented-need cases.65
- Support quality65
- Price transparencyset by partner clinic; ~$200-300/mo range commonly reported for compounded GLP-160
- Longitudinal retentionlargest 503A in US; April 2025 Lilly suit + September 2025 AZ inspection + April 30 2026 503B-exclusion proposal (signaling broader compounded-GLP-1 sunset) stack into a tightening overhang. 503A medical-necessity path persists but volume thesis weakens.55
Brand pharmacy supply stable. Compounded channel sunsetting · April 30, 2026 FDA proposal to exclude tirzepatide from the 503B bulks list (comment closes June 29, final rule likely Q3 2026) closes the mass-compounded path. 503A patient-specific compounding survives only with documented medical necessity. Telehealth platforms (Hims, Ro, Mochi) pivoting toward brand prescriptions or oral alternatives.
Recovered from the 2023 shortage. Diabetes-coded insurance straightforward.
Oral semaglutide. Niche fit for needle-averse patients. Lower bioavailability than injectable.
Recovered from the 2023-24 shortage. Insurance coverage expanding under 2025-26 employer plans. Oral Wegovy 25mg launched Jan 2026 at $149/mo · adds a needle-free path. Compounded semaglutide channel similarly narrowing under post-Feb-2025 enforcement-discretion rules.
Lilly-direct LillyDirect channel (US-only) supplements pharmacy distribution. Stable. Brand-channel demand expected to lift through 2026 as compounded pathway closes under the April 30 FDA 503B-exclusion proposal · LillyDirect's at-launch pricing materially undercuts compounded for patients without insurance coverage.
The 11-signal rubric is public.
Identity, dose accuracy, COA, cold-chain, Rx legality, compound identity, endotoxin testing, refund posture, channel clarity, support quality, price transparency, longitudinal retention. Each scored 0 to 100. Vendors that fail our floor are silently filtered out · they don't appear in our match flow at all.
If Strive Pharmacy wants to dispute or update this score, contact partner@panya.health. Score updates are recorded on this page with a public changelog.
Want a match for your situation?
Take the 2-minute quiz. We'll match you against this and the other vendors in your region · based on your dose, urgency, and budget.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.